346 related articles for article (PubMed ID: 22341130)
1. Polyepitope protein incorporated the HIV-1 mimotope recognized by monoclonal antibody 2G12.
Karpenko LI; Scherbakova NS; Chikaev AN; Tumanova OY; Lebedev LR; Shalamova LA; Pyankova OG; Ryzhikov AB; Ilyichev AA
Mol Immunol; 2012 Apr; 50(4):193-9. PubMed ID: 22341130
[TBL] [Abstract][Full Text] [Related]
2. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
3. Artificial polyepitope HIV-1 immunogen containing mimotope of 2F5 epitope.
Shcherbakova NS; Shcherbakov DN; Bakulina AY; Karpenko LI; Ryzhikov AB; Ilyichev AA
Protein Pept Lett; 2016; 23(2):159-68. PubMed ID: 26655727
[TBL] [Abstract][Full Text] [Related]
4. Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma.
Humbert M; Antoni S; Brill B; Landersz M; Rodes B; Soriano V; Wintergerst U; Knechten H; Staszewski S; von Laer D; Dittmar MT; Dietrich U
Eur J Immunol; 2007 Feb; 37(2):501-15. PubMed ID: 17236253
[TBL] [Abstract][Full Text] [Related]
5. A synergistic effect of a combined bivalent DNA-protein anti-HIV-1 vaccine containing multiple T- and B-cell epitopes of HIV-1 proteins.
Bazhan SI; Karpenko LI; Lebedev LR; Uzhachenko RV; Belavin PA; Eroshkin AM; Ilyichev AA
Mol Immunol; 2008 Feb; 45(3):661-9. PubMed ID: 17869341
[TBL] [Abstract][Full Text] [Related]
6. [Localization of the HIV-1 gp120 conformational epitope recognized by virus neutralizing monoclonal antibodies 2G12].
Tumanova OIu; Kuvshinov VN; Il'ichev AA; Nekrasov BG; Ivanisenko VA; Kozlov AP; Sandakhchiev LS
Mol Biol (Mosk); 2002; 36(4):657-63. PubMed ID: 12173470
[TBL] [Abstract][Full Text] [Related]
7. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
8. Binding of high-mannose-type oligosaccharides and synthetic oligomannose clusters to human antibody 2G12: implications for HIV-1 vaccine design.
Wang LX; Ni J; Singh S; Li H
Chem Biol; 2004 Jan; 11(1):127-34. PubMed ID: 15113002
[TBL] [Abstract][Full Text] [Related]
9. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC
J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346
[TBL] [Abstract][Full Text] [Related]
10. Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation.
Tian H; Xiao Y; Qin L; Chen YH
Immunobiology; 2001 Dec; 204(4):434-41. PubMed ID: 11776398
[TBL] [Abstract][Full Text] [Related]
11. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of Artificial Immunogens Containing Peptide Mimotopes of HIV-1 Epitopes Recognized by Monoclonal Antibodies 2F5 and 2G12.
Shcherbakova NS; Chikaev AN; Rudometov AP; Shcherbakov DN; Il'ichev AA; Karpenko LI
Bull Exp Biol Med; 2019 Jun; 167(2):259-262. PubMed ID: 31243678
[TBL] [Abstract][Full Text] [Related]
13. Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response.
Charles-Niño C; Pedroza-Roldan C; Viveros M; Gevorkian G; Manoutcharian K
Vaccine; 2011 Jul; 29(32):5313-21. PubMed ID: 21600948
[TBL] [Abstract][Full Text] [Related]
14. Protection against measles virus-induced encephalitis by anti-mimotope antibodies: the role of antibody affinity.
Olszewska W; Obeid OE; Steward MW
Virology; 2000 Jun; 272(1):98-105. PubMed ID: 10873752
[TBL] [Abstract][Full Text] [Related]
15. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
Haynes BF; Torres JV; Langlois AJ; Bolognesi DP; Gardner MB; Palker TJ; Scearce RM; Jones DM; Moody MA; McDanal C
J Immunol; 1993 Aug; 151(3):1646-53. PubMed ID: 8335949
[TBL] [Abstract][Full Text] [Related]
16. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
17. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection.
Okuda K; Kaneko T; Yamakawa T; Tanaka S; Shigematsu T; Yamamoto A; Hamajima K; Nakajima K; Kawamoto S; Phanuphak P
J Mol Recognit; 1993 Sep; 6(3):101-9. PubMed ID: 8060667
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 V3 loop crown epitope-focused mimotope selection by patient serum from random phage display libraries: implications for the epitope structural features.
Gazarian KG; Palacios-Rodríguez Y; Gazarian TG; Huerta L
Mol Immunol; 2013 Jun; 54(2):148-56. PubMed ID: 23270686
[TBL] [Abstract][Full Text] [Related]
19. 10E8-like neutralizing antibodies against HIV-1 induced using a precisely designed conformational peptide as a vaccine prime.
Yu Y; Tong P; Li Y; Lu Z; Chen Y
Sci China Life Sci; 2014 Jan; 57(1):117-27. PubMed ID: 24369352
[TBL] [Abstract][Full Text] [Related]
20. Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization.
Berzofsky JA
Biotechnol Ther; 1991; 2(1-2):123-35. PubMed ID: 1726961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]